Partner portal 
19001717 
Evaluate multiple types of lung cancer by a single panel
Lung cancer is not a single disease but a group of malignancies with distinct histological subtypes and biological characteristics. Because no single tumor biomarker provides sufficient sensitivity or specificity across all subtypes, a multi-marker approach offers a more comprehensive assessment.
- Carcinoembryonic antigen (CEA) is more commonly elevated in lung adenocarcinoma.
- CYFRA 21-1 and SCC antigen are more informative in lung squamous cell carcinoma.
- Neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP) are valuable biomarkers for small cell lung cancer.
- Interleukin-6 (IL-6) reflects systemic inflammation and may provide additional information regarding disease activity and prognosis.
Combining multiple tumor biomarkers improves the clinical value of testing by supporting prognostic assessment, treatment monitoring and the early detection of disease recurrence.
Computed tomography (CT), particularly low-dose CT, and chest X-ray are important imaging modalities for detecting pulmonary abnormalities.
If you are at high risk of lung cancer, physicians may still recommend regular imaging screening to reduce the likelihood of missing disease at an early stage, even when your blood test results are completely normal.
Early-stage lung cancer often causes few or no noticeable symptoms. However, several warning signs should not be ignored, including:
- Persistent cough lasting longer than 2 – 3 weeks.
- Hemoptysis or blood-streaked sputum, even in small amounts.
- Unexplained shortness of breath.
- Persistent hoarseness or ongoing chest pain.
- Persistent fatigue despite adequate rest.
